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Abstract 
Background: Emergence of resistance against integrase inhibitor raltegravir in human immunodeficiency virus type 
1 (HIV-1) patients is generally associated with selection of one of three signature mutations: Y143C/R, Q148K/H/R or 
N155H, representing three distinct resistance pathways. The mechanisms that drive selection of a specific pathway are 
still poorly understood. We investigated the impact of the HIV-1 genetic background and population dynamics on the 
emergence of raltegravir resistance. Using deep sequencing we analyzed the integrase coding sequence (CDS) in lon-
gitudinal samples from five patients who initiated raltegravir plus optimized background therapy at viral loads > 5000 
copies/ml. To investigate the role of the HIV-1 genetic background we created recombinant viruses containing the 
viral integrase coding region from pre-raltegravir samples from two patients in whom raltegravir resistance devel-
oped through different pathways. The in vitro selections performed with these recombinant viruses were designed to 
mimic natural population bottlenecks.
Results: Deep sequencing analysis of the viral integrase CDS revealed that the virological response to raltegravir 
containing therapy inversely correlated with the relative amount of unique sequence variants that emerged suggest-
ing diversifying selection during drug pressure. In 4/5 patients multiple signature mutations representing different 
resistance pathways were observed. Interestingly, the resistant population can consist of a single resistant variant that 
completely dominates the population but also of multiple variants from different resistance pathways that coexist in 
the viral population. We also found evidence for increased diversification after stronger bottlenecks. In vitro selections 
with low viral titers, mimicking population bottlenecks, revealed that both recombinant viruses and HXB2 reference 
virus were able to select mutations from different resistance pathways, although typically only one resistance pathway 
emerged in each individual culture.
Conclusions: The generation of a specific raltegravir resistant variant is not predisposed in the genetic background 
of the viral integrase CDS. Typically, in the early phases of therapy failure the sequence space is explored and multiple 
resistance pathways emerge and then compete for dominance which frequently results in a switch of the dominant 
population over time towards the fittest variant or even multiple variants of similar fitness that can coexist in the viral 
population.
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Background
Currently, viral replication is successfully suppressed in 
the majority of HIV-infected patients treated with com-
bination antiretroviral therapy (cART) [1]. However, 
virological failure associated with the emergence of drug 
resistant viruses may still limit the success of cART. The 
emergence of drug resistance in HIV is a direct conse-
quence of the high error-rate of the HIV reverse tran-
scriptase (RT) enzyme [2–4]. The frequent incorrect 
nucleotide incorporations result in evolution of the viral 
population and generate a myriad of viral variants upon 
which selective forces may act. The population size and 
replication rate are important viral parameters that con-
tribute to the probability that resistance emerges and to 
how HIV-1 drug resistance evolves [5–9].
Integrase inhibitors comprise a class of antiretroviral 
drugs that specifically prevent the integration of the viral 
genome into the human genome. Raltegravir is the first 
representative of a class of integrase inhibitors that tar-
get the strand transfer reaction (INSTIs) of the viral DNA 
into the host genome which is performed by the viral 
enzyme integrase. Like other INSTIs, raltegravir prefer-
entially binds and inhibits the viral DNA-integrase com-
plex (intasome) over unbound integrase [10–12].
It was the first integrase inhibitor used in clinical prac-
tice (since 2007) but was recently registered by the FDA 
for once daily dosing [13] and is very well tolerated [14] 
due to a low toxicity profile [15]. Resistance is commonly 
associated with selection of one of the signature ralte-
gravir resistance mutations Y143C/R/H, Q148H/K/R or 
N155H [16–18]. Mutations at each of these three amino 
acids represent a distinct resistance pathway and all sig-
nature mutations are associated with reductions in viral 
replication [17, 19, 20]. Accumulation of secondary resist-
ance mutations is often associated with a greater loss of 
drug susceptibility and/or improved viral fitness [21–23]. 
Different mutational combinations vary greatly in their 
impact on raltegravir susceptibility and viral replica-
tion. In general, substitutions at amino acid position 148 
confer higher levels of resistance than substitutions at 
amino acid Y143 or N155. The G140S plus Q148H com-
bination is considered the most resistant variant and has 
little effect on viral replication. The resistance patterns 
observed in HIV-1 patients on a raltegravir containing 
regimen are very diverse and Q148H/K/R (usually with 
G140A/C/S and/or E138A/K) and N155H (often together 
with E92Q or V151I) mutations are observed more fre-
quently than Y143 mutations [24]. The different resistance 
pathways are believed to be mutually exclusive and multi-
ple primary mutations (especially 148 +  155 mutations) 
are generally not observed on the same viral genome [25]. 
Remarkably, replacement of the dominant resistant pop-
ulation by a viral population with a completely different 
resistance pattern during continuous non-suppressive 
INSTI therapy has been observed [26–29].
The mechanisms that drive selection and switching of 
resistance pathways are inadequately understood. Under-
standing these mechanisms is essential in view of other 
INSTIs that are in clinical use (elvitegravir and dolutegravir) 
or in clinical trial (bictegravir and cabotegravir), since their 
resistance profiles partially overlap with that of raltegravir 
[25]. For instance, raltegravir resistance mutations Q148H/
K/R and N155H show a high level of cross-resistance with 
elvitegravir, but elvitegravir susceptibility is unaffected by 
Y143 mutations [30, 31], a difference that is beautifully 
explained by crystal structures of the intasome in presence 
of raltegravir or elvitegravir [11]. The VIKING studies dem-
onstrated dolutegravir’s superior resistance profile attested 
by sustained activity against all raltegravir resistant variants, 
except for viruses with a mutation at amino acid 148 in com-
bination with at least one secondary mutation at position 138 
and/or 140 [32–34]. These observations were corroborated 
by in vitro analysis of resistance profiles [35–37] which also 
uncovered two atypical INSTI resistance mutations (G118R 
and F121Y) that confer pan-INSTI resistance [38, 39].
We investigated the impact of the HIV-1 genetic back-
ground and population size on the evolution of raltegra-
vir resistance and their role in determining selection of 
a particular resistance pathway. Using next-generation 
sequencing (NGS) we analyzed patient-derived viral 
integrase sequences from samples taken before and dur-
ing raltegravir therapy failure. Frequency and dynamics 
analysis of the deep sequencing data was used to evaluate 
intra-patient evolution of resistance.
To investigate the role of the genetic background we 
generated recombinant viruses containing the viral 
integrase CDS from pre-raltegravir samples from two 
patients experiencing virological failure receiving ralte-
gravir therapy. With these recombinant viruses we con-
ducted multiple low multiplicity of infection (MOI) 
in vitro selections in parallel, with the advantage that all 
resistant variants generated are allowed to replicate and 
different raltegravir resistance pathways can be identified.
Results
During raltegravir resistance development, multiple 
resistant variants emerge that compete to become the 
dominant variant
We studied five patients who initiated raltegravir ther-
apy as part of a cART regimen and subsequently dem-
onstrated virological failure to the raltegravir containing 
regimen. Of note, all 5 patients were heavily pre-treated 
and raltegravir was part of a (partly) compromised back-
bone. This may partially explain the moderate virological 
responses and limited therapy success in these patients. 
Patient (Pt) 1, Pt2, Pt3 and Pt5 were infected with HIV-1 
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subtype B strains, Pt4 was infected with a HIV-1 CRF02_
AG strain. All patients started raltegravir therapy with 
viral loads  >  5000 copies/ml (c/ml) of HIV-1 RNA, as 
measured in the last viral load test before initiation of 
raltegravir therapy. To investigate if the emerged resist-
ant variants existed as minority variants before raltegravir 
therapy and how the resistant population evolved we ana-
lyzed longitudinal samples from these patients by NGS.
Patient 1
HIV-1 RNA initially decreased after start of raltegravir con-
taining cART (2.2 log decrease in HIV-1 RNA), but the viral 
load rebounded quickly after therapy initiation (< 81 days, 
Fig.  1a). Population sequencing revealed presence of 
raltegravir resistance mutations (E138E/K  +  Q148Q/
K/R +  N155H/H) and raltegravir was discontinued from 
the regimen after 124 days. NGS revealed very small popu-
lations at baseline containing Q148R and E138K (0.1% of 
the population, Fig. 2a), but they were not present on the 
same genomes (Fig.  2b). 40  days after start of raltegravir, 
virus with Q148R had increased to 1.7% of the popula-
tion and virus with E138K + Q148K had increased to 0.5% 
(Fig. 2a, b). These two variants dominated the population 
after 90 days (red nodes, Fig. 1a) but a third resistant vari-
ant appeared, N155H which already comprised 13% of 
the population. In the subsequent sample (153  days after 
start of raltegravir, black nodes Fig. 1a) the N155H variant 
replaced the Q148R variant and dominated the population 
together with the E138K  +  Q148K variant. Surprisingly, 
4  weeks after raltegravir discontinuation, wild-type virus 
had not reseeded the viral population which was consisted 
entirely of raltegravir resistant variants (Fig. 2).
Patient 2
Pt2 was off therapy for a few weeks due to toxicity related 
issues but a new five-drug regimen including raltegravir and 
darunavir resulted in a rapid decline of the viral load but was 
discontinued again because of darunavir-related toxicity 
(Fig. 1b). Shortly thereafter, the same regimen was restarted 
without darunavir resulting in a further decline of the viral 
load to undetectable levels. After brief virological suppres-
sion (HIV-1 RNA  <  50 c/ml, a 3.0 log decrease in HIV-1 
RNA), viral load rebounded and population sequencing 
showed gradual accumulation of raltegravir resistance muta-
tions: initially primary resistance mutation N155H appeared 
followed by two secondary resistance mutations, first Q95K 
and later V151I. NGS revealed no major raltegravir resist-
ance mutations at baseline or mutations at positions 143 or 
148 at any time-point, not even as minority variants (Fig. 2).
Patient 3
Pt3 only showed a partial virological response to the ralte-
gravir containing therapy (a 1.0 log decrease in HIV-1 RNA 
was observed) and full suppression was never achieved. The 
viral load rebounded shortly after start of raltegravir con-
taining cART (< 70 days, Fig. 1c) and the viral population 
contained N155H mutants. In a later time-point, 169 days 
after start of raltegravir, this population was replaced by a 
variant with primary mutation Y143R and several second-
ary mutations including L74M, T97A and G163E. NGS 
revealed only secondary mutations in the sample before 
raltegravir therapy, mostly as very low frequency variants 
(Fig. 2), including T97A and Y143C (both 0.2%). In a sam-
ple taken 28 days later, 77.5% of the population contained 
N155H, 15.4% had T97A and variants with Y143C were not 
detected anymore. In the subsequent sample 70 days after 
start of raltegravir therapy, N155H had increased to 88.6% 
and Y143C had reappeared in 11.8% of the reads. Y143C and 
N155H did not appear to be on the same genome (Fig. 2b). 
After 169 days the resistant population had shifted dramati-
cally, with Y143R making up 99.7% of the population and 
complete absence of N155H. Mutations L74M, T97A and 
G163R appeared in nearly the entire viral population.
Patient 4
Pt4 was also a partial responder (1.1 log decrease in HIV-1 
RNA) in whom virological suppression was not achieved 
during 48 weeks of raltegravir containing therapy. Sanger 
sequencing revealed only very small (< 20%) populations 
of Q148H/Q148R and N155H and resistant variants never 
dominated the population (Fig.  1d). Before raltegravir 
therapy, mutation Y143H was detected at low frequency 
(0.2%) by NGS but did not appear in any of the later 
samples during raltegravir treatment. In samples 8 and 
81 days after start of raltegravir therapy also no significant 
raltegravir resistance mutations were observed (Fig.  2a). 
However, in the sample 123 days after raltegravir therapy 
initiation several primary and secondary raltegravir resist-
ance mutations occurred. N155H was found in 14.4%, of 
the population, Q148H in 7.5% of which approximately 
half (4.1%) in combination with G140S and the remainder 
in combination with E157D (Fig. 2b). Q148R was present 
in 2.4% of the population and G163R in 2.7%.
Patient 5
In addition to a compromised backbone, this patient also had 
sub-therapeutic levels of raltegravir levels due to a drug–drug 
interaction with rifampicin (an interaction unknown at time 
of raltegravir prescription). Despite the suboptimal levels 
of raltegravir, switching to a raltegravir containing regimen 
quickly resulted in complete viral suppression (< 26 days, 3.3 
log decrease in HIV-1 RNA) but viral load rebounded within 
21 weeks (Fig. 1e). Population sequencing (sample 457 days 
after initiation of raltegravir) demonstrated that virus with 
integrase substitutions G140S +  Q148H completely domi-
nated the viral population.
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No major resistance mutations were detected at base-
line by NGS. Interestingly, in the first sample during 
therapy failure (blue nodes Fig.  1e) mutations from 
all three major resistance pathways including double 
mutants with secondary mutations were observed with 
G140S  +  Q148H being the most frequently occurring 
double mutant (Fig.  2). In this sample the variant with 
mutation N155H was the dominant variant but was out-
competed in the subsequent sample (red nodes Fig.  1e) 
by double mutant G140S + Q148H.
Evidence for elevated diversification following extinction 
from drug pressure on large viral populations
To get an impression of the evolution of the viral popu-
lation during raltegravir pressure we analyzed how the 
number of derived sequences and unique variants related 
to the viral load. To allow for easy comparisons, each of 
these measures were normalized on a 0–1 scale and plot-
ted in the same graph (Fig. 3, left panels). In all patients, 
the total number of derived sequences and the number 
of unique variants detected correlated with the viral load 
(See figure on previous page.) 
Fig. 1 Development of raltegravir resistance during raltegravir containing cART. Left hand panels: therapy history, HIV-1 RNA load,  CD4+ cell count 
and resistance mutations detected by population sequencing of five patients receiving raltegravir therapy. All viral load measurements are marked 
by a solid black circle. The  CD4+ cell counts are represented by open triangles. Samples analyzed by 454 deep sequencing are marked by colored 
circles. Resistance mutations detected by Sanger population sequencing are indicated in boxes. Only raltegravir resistance associated mutations 
are given. Right hand panels: evolution of resistance pathways, deep sequence analysis of the integrase core domain. Data was obtained by 454 
pyrosequencing. Relevant resistance mutations are indicated at the respective nodes. Figures were generated using the nucleotide sequences and 
the redundancy-level for calling a variant was set at 80. No mutation information indicates wild-type amino acids. The size of each node is scaled to 
reflect the relative abundance and viral load at each time point and patient. Time points are indicated by color and correspond to the colored circles 
in the left hand panels: green is the baseline sample, blue the first sample after raltegravir therapy initiation; red is the second sample after raltegravir 
therapy initiation; black is the final sample after raltegravir therapy initiation. In patient 3 gold is another baseline sample predating the green sample
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mut. - - L - K R - - K S / C - R / K I H - K - - 138K+148K 5524 95R+148R 61 140C+148R 11 92K+148R 10
216631819575/562311/980865160121.qerf505010068109 138K+148R 136 72L+148K 12 148R+155H 11
1.00.312.08.45/1.131.0/8.01.456.01.01.0)%( 140S+148R 89 148K+157K 12 138K+155H 10
mut. - - - - Q - A - K A / C / S - R / K I H N - - R / E 138K+148K 4073 138K+155H 131 138K+148K+155H 54 140A+148R 31 140S+148R+156N 13 92Q+138K+148K 10
1/893102546717714/62331/14/21134348245.qerf801900032351 0 138K+148R 193 155H+163R 98 92Q+155H 44 97A+138K+148K 16 97A+155H 12
1.0/1.11.06.949.19.54/6.31.0/5.0/2.17.743.06.0)%( 151I+155H 176 138K+140A+148K 81 140C+148R 41 140S+148R 13 155H+163E 10
days since HIV-1 reads baseline aa T L V/I L E Q T F E G Y Q V N K E K G Double mutant        n
raltegravir RNA load codon 66 68 72 74 92 95 97 121 138 140 143 148 151 155 156 157 160 163
mut. I V I / T - - - - - - - - - I - - Q / K - E -
-45 51600 8714 freq. 12 15 4815 / 14 14 18 / 16 14
(%) 0.1 0.2 55.3 / 0.2 0.2 0.2 / 0.2 0.2
mut. - - I / L - - K - - - - - - - H N K - - 95K+155H 130
Paent 233 643 6995 freq. 6965 / 11 130 4648 54 39
2 (%) 99.6 / 0.2 1.9 66.4 0.8 0.6
mut. I - I - - K A - - - - - I H - - R - 95K+155H 6439 155H+160R 124 95Q+97A+155H 13
0612977469313966408741.qerf408700021482 151I+155H 949 95Q+155H+160R 36
1.28.994.212.08.580.0012.0)%( 95K+151I+155H 193 151I+155H 14
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2.515.770014.512.08.0)%( 72V+155H 35 72V+97A+163R 11
mut. - - L M - - A / I - - - C - I H - G - R all mutants include 151I 74M+97A+143C+163R  407 155H+157G+163R 12
8581219523086353411/713171401.qerf0863058507 155H+163R 867 97A+155H 338 97I+155H 11
5.053.06.880018.113.0/8.533.113.0)%( 97A+155H+163R 544 97A+143C+155H+163R  18
mut. - - L / V M G R A L / S G - R / P - I S / D - G E R all mutants include 74M+97A+143R+151I+163R 92G 12 155D 12 72V+163R 11
169 11000 4832 freq. 58 / 11 4675 12 11 4832 19 / 15 12 4819 / 13 4832 12 / 12 13 11 4832 72L+163R 58 121S 15 138G 12 95R 11 except:
(%) 1.2 / 0.2 96.8 0.2 0.2 100 0.4 / 0.3 0.2 99.7 / 0.3 100 0.2 / 0.2 0.3 0.2 100 121L 19 157G 13 155S 12 160E 11 L74+97A+143R+151I+163R  157
days since HIV-1 reads baseline aa T L I L E Q T F E G Y Q V N K E K G Double mutant n
raltegravir RNA load codon 66 68 72 74 92 95 97 121 138 140 143 148 151 155 156 157 160 163
mut. - - L / V - G - A - G - H - A D - - R - -
-143 15000 4951 freq. 186 / 68 11 10 18 12 11 12 12
(%) 3.8 / 1.4 0.2 0.2 0.4 0.2 0.2 0.2 0.2
mut. - - T / V / L - - - - L - - - - - D - - - - -
112197/071/671.qerf955400468
Paent 2.03.07.1/7.3/9.3)%(
4 mut. - S L - - - I L / S G - - - A - E - - - -
01810121/22016511.qerf0445007218
2.03.02.02.0/4.02.00.12.0)%(
mut. - - L / S - - R A S - S - H / R M H - D - R 140S+148H 198
43176130791711/56389101312123/49.qerf38840097321 148H+157D 167
7.24.34.414.04.2/5.71.42.03.02.07.0/9.1)%( 72L+155H 24
days since HIV-1 reads baseline aa T L I L E Q T F E G Y Q V N K E K G Double mutant n
raltegravir RNA load codon 66 68 72 74 92 95 97 121 138 140 143 148 151 155 156 157 160 163
mut. - - - - - - - - - - - - I D - K - - -
-2 77000 3897 freq. 26 11 12
(%) 0.7 0.3 0.3
mut. - - - - - - - - - S R / C H I H N - - - 140S+148H 54 143R+155H 16
215 8000 1313 freq. 54 424 / 41 66 23 767 31 155H+156N 31
Paent (%) 4.1 32.3 / 3.1 5 1.8 58.4 2.4 151I+155H 23
5 mut. - - - - - - - - - S - H - - - - - - 140S+148H 1342
341 16000 1342 freq. 1342 1342
(%) 100 100
mut. - - V - G - - - - S - H - - - - - - 140S+148H 3650
-056305631111.qerf056300042754 72V+140S+148H 11
-0010013.03.0)%( 92G+140S+148H 11
Fig. 2 Analysis of the longitudinal 454 deep sequencing data. a Analysis of the frequency of all non-synonymous mutations detected by deep 
sequencing at the 18 codons associated with raltegravir resistance. Only unique variants with a minimum of 10 reads were included in the analysis. 
Total number of reads and the proportion of reads containing the denoted mutations relative to the total number of reads are given. Mutations 
of interest are highlighted by colored boxes. Similar colored boxes are mutations that appeared to be on the same genome. Red boxes indicate 
mutations from the Q148 pathway, yellow boxes indicate the Y143 pathway and green boxes the N155 pathway. b Sequences containing multiple 
mutations are shown. Double mutants are sorted by frequency
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(R = 0.29–0.95). However, in a few cases either the num-
ber of sequences detected (Pt1 and Pt4) or the number 
of unique variants (Pt5) showed weaker correlations and 
thus we also investigated the population diversity relative 
to the viral load. Therefore, the normalized number of 
sequences and unique variants were divided by the nor-
malized viral load respectively (Fig. 3, right panels). Inter-
estingly, in patients 1, 2 and 5, the proportion of unique 
sequence variants appeared to increase when the viral 
load dropped. This suggests a sudden diversifying pres-
sure on the viral population. In contrast, in patients 3 and 
4 there appeared to be no correlation between the rela-
tive number of unique variants and the viral load which 
coincided with the smallest reductions in viral load dur-
ing raltegravir containing cART (Fig.  1c, d). These data 
indicate that the stronger the bottleneck is (i.e. largest 
reduction in viral load), the larger the effect is on subse-
quent diversification. Thus, extinction due to antiretrovi-
ral treatment appears to induce diversification.
The genetic background is not paramount for the 
emerging INSTI resistance pathway
To investigate the role of the viral genetic background in 
determining the raltegravir resistance pathway we cloned 
the integrase coding region from pre-raltegravir therapy 
samples from two patients (Pt1 and Pt2) in an HXB2 
reference background. These recombinant viruses were 
derived from amplicons of pre-raltegravir samples with 
a viral load of 21,800 and 51,600  c/ml respectively, cre-
ating libraries containing thousands of patient-derived 
sequences for both samples.
In these patients, raltegravir resistance developed 
through different pathways during raltegravir ther-
apy. In Pt1, resistance developed initially through 
E138K + Q148K and later a second variant emerged with 
N155H (Fig. 1a). In Pt2, raltegravir resistance developed 
initially through N155H and was complemented by two 
secondary mutations, Q95K and V151I, which made up 
nearly 100% of the viral population during prolonged 
therapy failure (Fig.  1b). With the recombinant viruses 
of these raltegravir baseline samples and HXB2 reference 
virus (molecular clone from pHXB2AF, therefore a single 
sequence input per replicate) multiple in vitro selections 
were performed in parallel.
All cultures were maintained for 10 serial passages to 
a final concentration of 1024 nM raltegravir. HXB2 virus 
predominantly selected mutation Q148K (in three out 
of the five independent cultures), N155H was selected 
once and in one culture only secondary resistance muta-
tions emerged (Fig. 4). Two of the Q148K mutations were 
(See figure on previous page.) 
Fig. 3 Viral load versus total number of sequences and number of unique variants. Left panels: the normalized (range 0–1) viral load, number of 
detected sequences and unique number of variants. The correlation coefficient, R, is indicated for the comparisons to the viral load. Right panels: 
the relative number of derived sequences and the number of unique variants relative to the viral load. Figures were generated using the nucleotide 
sequences and the redundancy-level for calling a variant was set at 80
Integrase
position 68 72 74 92 121 138 140 143 148 151 155 163 230 232 233 265 280
HXB2 aa L V L E F E G Y Q V N G S N P A C
n = 5
# 1 HXB2 - - - - - - A - K - - - - - - - -
# 2 HXB2 - - M - Y - - - - I - R - - - - -
# 3 HXB2 - V/I - - - K - - K - - - - - - - -
# 4 HXB2 - - - - - A - K - - - - - - - -
# 5 HXB2 - - - Q - - - - - I H - - - - - -
n = 5 baseline aa I D V
# 1 pt1 (148 pathway) - I - - - K C - K - - - - D - V -
# 2 pt1 (148 pathway) - I L/M - - - - C - - H R S/K/R/N D - V -
# 3 pt1 (148 pathway) - I - - - - - R - - H - - D S V -
# 4 pt1 (148 pathway) - I - - - - S - R - - - - D - A -
# 5 pt1 (148 pathway) - I - - - - S - H - - - - D - V -
n = 5 baseline aa V/I D
# 1 pt2 (155 pathway) - I - - - - S - H - - R - D - - -
# 2 pt2 (155 pathway) - - - - - - S - H - - - - H - - Y
# 4 pt2 (155 pathway) V I - - - - - - - - - - - D - - -
Fig. 4 Raltegravir in vitro selections with patient-derived integrase recombinant viruses. Raltegravir concentration was doubled in each serial 
passage to a final concentration of 1024 nM of raltegravir in passage 10. All differences from the HXB2 reference sequence are given and mutations 
emerging during the raltegravir in vitro selections in the viral integrase coding region are indicated in red. The indicated mutations were detected 
by population sequencing of viral RNA in the culture supernatants from passage 10. Cultures 3 and 5 from Pt2 were discontinued due to failed virus 
propagation
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accompanied by G140A, the third by E138K. G140S was 
probably not selected because it required two nucleotide 
changes in this HXB2 background; G140A and E138K 
required just one. The N155H-virus additionally acquired 
mutations V151I and later E92Q. Amino acid substitu-
tions at residue 143 were not observed. In vitro selections 
with Pt1 recombinant virus yielded amino acid substi-
tutions at all three major resistance positions. Again, 
Q148 mutations dominated (3/5  cultures). Interestingly, 
in the two other cultures, N155H emerged in combina-
tion with amino acid substitutions at position 143 (one 
with Y143C and one with Y143R, Fig.  4). The muta-
tions selected in  vitro differed remarkably from what 
was observed in  vivo. The difference between in  vivo 
and in vitro resistance was even more profound for Pt2. 
In  vivo, only mutations relating to the N155H pathway 
were observed and no other significant mutations were 
detected by deep sequencing. In contrast, in  vitro only 
mutations from the Q148 pathway were detected (Fig. 4). 
Cultures #1 and #2 both developed raltegravir resistance 
through G140S  +  Q148H. Culture #1 initially selected 
G140S  +  Q148R but later switched to Q148H (not 
shown). Two of the five cultures were not able to repli-
cate at higher raltegravir concentrations. When an earlier 
passage of both cultures was sequenced, no mutations 
in the viral integrase were found so these cultures were 
discontinued. A third culture only selected an L68V sub-
stitution, but this virus did not demonstrate phenotypic 
resistance when tested (data not shown).
Discussion
We investigated the impact of the genetic background 
and viral population size on the development and evo-
lution of raltegravir resistance in vitro and in vivo. Deep 
sequencing revealed presence of major raltegravir resist-
ance mutations at baseline in 3/5 patients (patients (1, 3 
and 4, Fig. 2a) at very low frequencies (≤ 0.2%). Only the 
major resistance mutation detected before therapy in Pt3, 
Y143C (0.2% in 2nd sample on day 0), ultimately became 
the dominant variant in the resistant population although 
it surprisingly disappeared from the subsequent sample 
to reappear in the 4th sample (11.8% on day 70). In the 
final sample (169 days) Y143C was not detected anymore 
but virus with mutation Y143R completely dominated 
the viral population. In the majority of subtype B viruses, 
the Y143R substitution requires two nucleotide changes 
(Y143 = TAC → TGC = 143C → CGC = 143R). So it 
appears that the Y143C variant detected at baseline 
facilitated selection of the more resistant Y143R variant 
[27] in this patient. In Pt 1, secondary resistance muta-
tion E138K was detected at baseline (0.1%) and appeared 
to have acquired Q148K as in the subsequent sample a 
double mutant with E138K + Q148K was detected (0.5%) 
which persevered in the population (44.7% in the final 
sample). This suggests that minor variants present at 
baseline can play a role in the development and evolu-
tion of raltegravir resistance but are not essential for the 
emergence of resistance [40–42], which is also seen for 
other drug classes [43, 44].
Remarkably, in Pt1 a variant with major mutation 
N155H and no apparent secondary resistance muta-
tions emerged after and then co-existed alongside 
the E138K  +  Q148K double mutant, each comprising 
roughly 50% of the viral population. This suggests a fit-
ness advantage for the N155H single mutant over the 
E138K + Q148K double mutant. This is unexpected con-
sidering the in  vitro observations regarding resistance 
and replication of these mutants [17, 45, 46]. A possible 
explanation could be the so-called hitchhiking effect; 
this particular variant had a fitness advantage that was 
located outside the investigated region. For instance, 
resistance against any of the other antiretrovirals in the 
therapy regimen (e.g. efavirenz) could have been present 
in this variant but not in the other variants. While the 
chances that this occurs in one of the minority variants 
and not in any of the dominant species are small, the pos-
sibility cannot be excluded. Another possible explana-
tion is that the variant with the N155H mutation is more 
fit than the E138K +  Q148K mutant in the presence of 
raltegravir in this particular setting due to other factors 
(e.g. specific viral genetic background, immunological 
host factors, etc.).
We also observed a correlation between the number of 
unique sequence variants emerging and the magnitude of 
the virological response. Good virological response in Pts 
1, 2 and 5 (> 2 log reductions in HIV-1 RNA) coincided 
with the number of unique sequence variants observed; 
the proportion of unique sequence variants increased 
when the viral load dropped. Pts 3 and 4 demonstrated 
moderate responses with viral load drops of around 1 
log and showed no change in the relative frequencies of 
unique variants over the course of sampling. This sug-
gests that in Pts 1, 2 and 5, treatment with raltegravir 
induced an elevated diversification to escape drug pres-
sure while in Pts 3 and 4 the pressure on the population 
seemed to occur to a much lesser extent. This observation 
reminds of the explosive diversifications on a macro-evo-
lutionary scale observed in other fields of biology after 
ice ages and the cataclysmic extinction of dinosaurs [47, 
48]. However, regardless of treatment efficacy, i.e. both 
in patients with less dramatic and more severe virus load 
reductions, raltegravir resistance mutations developed 
and multiple resistance pathways were observed in 4/5 
patients. The large extinction opens up previously occu-
pied niches for new virus variants, (1) such that all new 
mutations are accepted and not compete for resources 
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until the population regains a size limited by the carrying 
capacity of the system, or (2) most of the diversity pre-
existed as a permanent, extremely low frequency pool of 
highly diverse viruses persisting in the shadow of more 
fit and high frequency variants. Once the high frequency 
variants are eradicated (e.g. by newly introduced drugs) a 
glimpse of that diversity surfaces. The larger the impact 
on the high frequency variants (i.e. reduction in viral 
load) the larger the proportion of the low frequency pool 
appears (i.e. number of unique variants increases when 
the viral load drops). Subsequently, one or two of the 
low frequency variants gain fitness in the new environ-
ment and become dominant, lowering the mean diversity 
again. The same can be argued from the point of viral 
escape. If the viral population doesn’t have to go that low 
to find fit variants (in the new environment), the impact 
on viral load is also less severe.
The raltegravir in  vitro selections in which we mim-
icked population bottlenecking by using a low MOI 
allowing all resistant variants that are generated to 
emerge, clearly indicate that the resistance pathway that 
is selected to escape raltegravir pressure is not predis-
posed in the genetic background of the integrase CDS. 
Evaluation of the combined in vivo and in vitro data indi-
cates that stochastic selection plays a major role during 
the initial development of raltegravir resistance.
In conclusion, the development and evolution of ralte-
gravir resistance can be separated in multiple phases/
components: (1) minority variants present at baseline can 
contribute to the emergence of raltegravir resistance but 
this is not preordained and seems to occur arbitrarily; (2) 
during the viral load drop due to drug pressure a burst 
of new sequence variants emerges creating diversifying 
selection; (3) these new variants usually include multi-
ple raltegravir resistant variants (from multiple resist-
ance pathways) that can pass the imposed bottleneck; 
(4) competition of these resistant variants determines 
the ultimate shape of the viral population. The resistant 
population can be the product of a single variant that 
outcompetes all others and only one variant represents 
the population or multiple variants with a similar fitness 
emerge that coexist in the viral population.
Further investigation is needed to better assess the 
exact impact of baseline minority resistance variants and 
the population size on the development and evolution of 
raltegravir resistance and determine the clinical implica-
tions of these factors.
Conclusions
Emergence of resistance against integrase inhibitor ralte-
gravir in HIV-1 patients is generally associated with 
selection of one of three distinct resistance pathways. The 
mechanisms that drive selection of a specific pathway 
are still poorly understood. Using deep sequencing we 
observed an inverse correlation between the virologi-
cal response and the relative amount of unique sequence 
variants emerging, suggesting diversifying selection dur-
ing drug pressure. In 4/5 patients multiple signature 
mutations representing different resistance pathways 
were observed. In addition, in  vitro selections revealed 
that identical viral clones were also able to select muta-
tions from different resistance pathways indicating that 
raltegravir resistance is not predisposed in the genetic 
background of the viral integrase. Importantly, raltegra-
vir resistance develops progressively and discontinuation 
during early phases of therapy failure is justified to pre-
serve future options with second-generation INSTIs.
Methods
Genotypic analysis
Population sequencing
HIV-1 RNA was isolated using the Nuclisens Islolation 
kit (BioMérieux, Boxtel, The Netherlands). Briefly, 100 μl 
of sample was mixed with 900  μl lysisbuffer and 40  μl 
silica and incubated for 10 min at room temperature to 
allow binding of the nucleic acid to the silica particles. 
Unbound material was removed by several washing steps 
after which the RNA was eluted at 56 °C with 100 μl of 
40 ng/µl poly-A RNA. The isolated viral RNA was used 
to reverse transcribe and amplify the viral integrase cod-
ing region in a single-step reaction using the Titan One 
Tube RT-PCR kit (Roche). The RT-PCR was conducted 
with primers 5′INoutF1 (5′-GGA ATC ATT CAA GCA 
CAA CCA GA-3′; 4059–4081) and 3′INoutR1 (5′-TGT 
ATG CAG ACC CCA ATA TGT TG-3′; 5262–5241). The 
amount of amplified product was further enhanced in a 
second PCR using the Expand High fidelity kit (Roche) 
with primers 5′INinF1 (5′-TAT CTG GCA TGG GTA 
CCA GCA C-3′; 4143–4164) and 3′INinR1 (5′-TAG 
TGG GAT GTG TAC TTC TGA AC-3′; 5217–5195). 
All PCR-amplified products were purified using the 
QIAquick PCR purification kit (Qiagen, Leusden, The 
Netherlands). Sequence analysis was performed with the 
BigDye Terminator v3.1 Cycle Sequencing Kit (Applied 
Biosystems, Foster City, CA, USA). Integrase sequences 
were obtained using six primers: Intseq1 (5′-ATT GGA 
GGA AAT GAA CAA GT-3′; 4173–4192), Intseq2 (5′-
AGC AGA AGT TAT TCC AGC AG-3′; 4484–4503), 
INT-3 (5′-TTC GGG TTT ATT ACA G-3′; 4897–4912), 
INT-4 (5′-CTT GTA TTA CTA CTG C-3′; 4986–4971), 
Intseq-5 (5′-CTG GCT ACA TGA ACT GCT AC-3′; 
4470–4452) and 3′INinR2 (5′-GCT TTC ATA GTG ATG 
TCT ATA AAA CC-3′; 5178–5153). Sequence editing 
and contig assembly were performed using SeqScape 
v2.6 (Applied Biosystems) with HXB2 as a reference 
sequence.
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Next‑generation sequencing and data analysis
To examine the mutation frequencies within the viral 
integrase by pyrosequencing, RNA was reverse tran-
scribed and amplified in a single step in a touch-down 
PCR using bar-coded primers to enable 454 pyrose-
quencing with pooled amplicons. The integrase core 
domain from amino acid position 53 to amino acid 180 
was analyzed. All mutations in the viral integrase at 18 
different codons associated with raltegravir resistance 
[16, 20, 23, 45, 49–52] were evaluated and included 
amino acids: T66, L68, V72, L74, E92, Q95, T97, F121, 
E138, G140, Y143, Q148, V151, N155, K156, E157, K160 
and G163.
All amplicons were purified with AMPure magnetic 
beads (Agencourt, Beckman Coulter, Krefeld, Germany), 
quality checked and quantified using an Agilent 2100 Bio-
analyser (Agilent Life Sciences, Waldbronn, Germany) 
and picogreen using the fluorometer Fluostar Optima 
(BMG Labtech, Offenburg, Germany), respectively. After 
equimolar pooling of the amplicons, emulsion PCRs 
were performed. Pyrosequencing was done using prim-
ers A and B (Titanium emPCR kit Lib-L v2; Roche-454 
Life Sciences, Branford, CT, USA). After bead recovery 
and enrichment, approximately 250,000 beads per pool 
were loaded on one region of a GS FLX PicoTiter plate 
subdivided with a four-lane gasket. Pyrosequencing was 
performed on a Genome Sequencer FLX (Roche-454 Life 
Sciences). Sequence readings from the 454 pyrosequenc-
ing run were extracted directly from the Standard-Flow-
gram-Files (sff). Reads were pair-wise aligned against the 
integrase sequence of reference strain HXB2. Multiple 
mutations present in a single read were assumed to origi-
nate from the same genome.
The dynamics of the sequence populations were 
investigated on de-aligned sets to avoid artifacts due to 
inconsistent alignment gap placements using statistical 
functions in R [53]. For the analyses of the dominant vari-
ants in the populations, the redundancy-level for calling 
a variant was set at 80, i.e. only variants detected at least 
80 times were considered. This level resulted in a strict 
filter that removed all known 454-sequencing artifacts 
[54–56]. The resulting dominant variants were aligned 
using MAFFT [57] and distance matrices were estimated 
using the R library ape [58] under a F84 substitution 
model (the choice of substitution model had no effect on 
the subsequent analyses). The R library sna [59] was used 
to construct minimum spanning trees (MSTs) based on 
the distance matrices of patient’s HIV population. Nodes 
were scaled according to both viral load and the relative 
abundance of each detected variant at time of sampling. 
We tracked known resistance mutations on the edges and 
edge lengths were drawn arbitrary in order to make the 
resulting graphs easy to look at.
Construction of deletion clone HXB2∆INT
An HXB2 molecular clone (pHXB2AF) was used to con-
struct a molecular deletion clone lacking the integrase 
coding region. pHXB2AF is derived from pHXB2WT 
[60], which expresses the full length HIV-1 sequence 
HXB2 (9719  bp, Genbank accession number K03455.1), 
with all bacterial sequences non-essential for bacterial 
expression and replication removed.
The NdeI site present in Gp120 (at HXB2 nt 6404) was 
inactivated to create a unique NdeI site at the 3′ end of 
the integrase CDS. Therefore pHXB2AF was digested 
with NcoI (Roche Diagnostics, Almere, The Nether-
lands) and NheI (New England Biolabs, Ipswich, MA, 
USA) to remove a 1586 bp fragment containing the NdeI 
site. PCR, using  VentR ® DNA polymerase (New Eng-
land BioLabs) was performed on pHXB2AF with prim-
ers, NcoI-out (5′ CAC TAG AGC TTT TAG AGG AGC 
TTA AGA-3′; 5614–5640), NheI-out (5′-TTT TAT TAT 
TTC CAA ATT GTT CTC TTA-3′; 7296–7270) and 
NdeI-KO (5′-TCA GAT GCT AAA GCG TAT GAT ACA 
G-3′; 6390–6414). Primer NdeI-KO contained one silent 
nucleotide change (underlined) to inactivate the NdeI site 
in the PCR fragment. The amount of amplified product 
was further increased and enriched by performing a sec-
ond amplification using  VentR ® DNA polymerase with 
primers NcoI-in (5′-GAG CTT TTA GAG GAG CTT 
AAG AAT GAA-3′; 5619–5645), NheI-in (5′-ATT GTT 
CTC TTA ATT TGC TAG CTA TCT-3′; 7281–7255) 
and NdeI-KO. This PCR fragment was then digested with 
NcoI and NheI and ligated with the digested pHXB2AF, 
resulting in pHXB2AFNdeIKO which was confirmed by 
sequence analysis of the complete fragment.
Subsequently, the integrase coding region was removed 
from pHXB2AFNdeIKO. Therefore pHXB2AFNdeIKO 
was digested with MluNI (Roche) and NdeI (New Eng-
land BioLabs). The fragment between MluNI and the 
5′ end of integrase was restored by performing a PCR 
on pHXB2AF using primers RT19 (5′-GGA CAT AAA 
GCT ATA GGT ACA G-3′; 2454–2472) and NgoMIV-
INTlinker (5′-TAA TAT CAT ATG GAC AGC GTC 
GCC GGC ACT GAC TAA TTT ATC TAC TTG TTC-
3′). Primer NgoMIV-INTlinker contained two silent 
nucleotide changes with respect to pHXB2AFNdeIKO, 
thereby introducing a unique NgoMIV site (underlined 
4209–4214) in the PCR fragment. In addition to these 
nucleotide changes the primer NgoMIV-INTlinker con-
tains a linker sequence with a unique NdeI site and an 
AspI site. AspI was used to prevent re-ligation of the vec-
tor and the linker. The amount of amplified product was 
further increased and enriched by performing a second 
amplification using  VentR ® DNA polymerase with prim-
ers RT19new2 (5′-GGA CCT ACA CCT GTC AAC ATA 
ATT GG-3′; 2484–2509) and NgoMIV-INTlinker. The 
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PCR fragment was then digested with MluNI and NdeI 
and ligated with the digested pHXB2AFNdeIKO, result-
ing in a molecular deletion clone lacking the integrase 
coding region (pHXB2AFΔINT), which was confirmed 
by sequencing the complete fragment.
Generation of recombinant virus
To generate recombinant viruses, the second PCR as 
described in the population sequencing section, was 
performed with a different primer pair: forward primer 
NgoMIV-Int2 (5′-TTA GTC AGT GCC GGC ATC AGG 
AAA G-3′; 4200–4224) which contains a NgoMIV restric-
tion site (underlined) and reverse primer 3INinR2. The 
obtained integrase fragment and vector pHXB2AFΔINT 
were digested with restriction enzymes NgoMIV (New 
England BioLabs) and NdeI. The PCR product and vector 
pHXB2AFΔINT were ligated overnight at 4 °C using the 
Rapid Ligation System (Promega, Benelux, Leiden, The 
Netherlands). After ligation, plasmids were digested with 
AspI and subsequently transformed into competent cells. 
Bacteria were cultured overnight at 37 °C. Plasmid isola-
tion was performed using the QIAgen Plasmid Mini kit 
(Qiagen).
Viruses were generated by transfecting 293T cells with 
10 ug plasmid DNA using Lipofectamine 2000 reagent 
(Invitrogen) according the manufacturer’s protocol. Two 
days after infection cell free virus was harvested and the 
viral infectivity  (TCID50) was determined using end-
point dilutions in MT2 cells.
Viral and cell culture
Cells
SupT1 and MT-2 cells were maintained in RPMI 1640 
medium with l-glutamine (Lonza, Verviers, Belgium) 
supplemented with 10% FBS (FBS; Sigma-Aldrich, Zwi-
jndrecht, The Netherlands) and 10  µg/ml gentamicin 
(Invitrogen, Breda, The Netherlands). 293T cells were 
maintained in DMEM with l-glutamine (Lonza) supple-
mented with 10% FBS and 10 µg/ml gentamicin.
In vitro selection experiments
The raltegravir in  vitro selection experiments with two 
recombinant viruses that contained patient-derived inte-
grase CDS and HIV-1 reference strain HXB2 were each 
performed 5 times. The in vitro selections were initiated 
by infecting 2 × 106 SupT1 cells at a multiplicity of infec-
tion (MOI) of 0.001. The initial raltegravir concentration 
was 2  nM Raltegravir. Cultures were monitored daily 
for cytopatic effect (CPE) and twice a week half of the 
medium was replaced by fresh medium supplemented 
with raltegravir. When full blown CPE was observed, cell 
free virus was harvested. The raltegravir concentration 
was raised in each passage to a final concentration of 
1024  nM in passage 10. After passage 10, HIV-1 RNA 
was isolated from all cultures for genotypic analysis. As 
a control, in  vitro evolution experiments (10 passages) 
were performed with HXB2 reference strain (5 individual 
cultures) to monitor the evolution of the integrase CDS 
during culture in absence of inhibitor.
Phenotypic drug susceptibility analysis
Drug susceptibility was determined by a multiple cycle 
cell-killing assay [61]. MT-2 cells (4 × 104 in 200 µl RPMI 
10% FBS per well) were plated in 96-well microplates. 
Sample virus and reference virus were inoculated for five 
days on a single 96-well plate in the presence of threefold 
dilutions of raltegravir. Both sample virus and reference 
virus were inoculated at multiple MOIs to adjust for any 
differences in viral RC. Fold change (FC) values were 
calculated by dividing the mean 50% inhibitory concen-
tration  (EC50) for a sample virus by that of the HXB2 ref-
erence strain.
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